Hyperuricemia (HUA) has become a worldwide health issue, drawing increasing public attention. This study aimed to elucidate the roles of bile acids (BAs) and their associations with gut microbiota in a HUA rat model. We established normal control (N) and HUA rat groups, then characterized the BA profiles in liver, serum, and ileum contents using a targeted metabolomics approach. Additionally, gut microbiota composition was analyzed through 16S rDNA gene sequencing. The results were that hyperuricemia induced elevated levels of cholic acid (CA) in liver and elevated levels of taurocholic acid (TCA), glycocholic acid (GCA), and taurodeoxycholic acid (TDCA) in the ileum content, particularly the increases in the levels of total 12α-hydroxy bile acid in the ileum content, which were consistent with the increased levels of CA in the liver. These changes are correlated to an increase in the abundance of the genera Allobaculum and Bifidobacterium . Our investigation revealed the fluxes of bile acids and their association with gut microbiota in HUA and provides new ideas for the study of metabolic diseases in hyperuricemia.
Periodontal disease is the most common oral chronic inflammatory disease in humans. Recent studies have indicated that red light Photobiomodulation (PBM) could inhibit cell inflammation effectively, but the effect of different doses of PBM on the treatment of inflammation has to be improved. Thus, this study was aimed to investigate the effects of various doses of PBM (630 ± 30 nm, (1) 5 mW/cm2, 1 J/cm2, 200 s; (2) 5 mW/cm2, 3 J/cm2, 600 s; (3) 5 mW/cm2, 9 J/cm2, 1800 s; (4) 5 mW/cm2, 18 J/cm2, 3600 s; (5) 5 mW/cm2,36 J/cm2, 7200 s) on the anti-inflammatory response of human gingival fibroblasts. Our results suggested that PBM (630 ± 30 nm) with doses of 18 J/cm2 and 36 J/cm2 could significantly inhibit the production of inflammatory cytokines such as Prostaglandin E2 (PGE2) and IL-8, presumably due to the fact that a high dose of PBM treatment could reduce intracellular Reactive oxygen species (ROS) in human gingival fibroblasts, thus reducing the expression of COX-2 enzyme. In addition, it was found that treatment with different doses of PBM (630 ± 30 nm) did not result in reduced mitochondrial membrane potential and mitochondrial dysfunction in human gingival fibroblasts. Our study provides a theoretical reference for the selection of PBM parameters and the application of PBM in the clinical treatment of periodontitis.
Dear Editor,Acrylamide is widely used in industry. Its monomer can enter the human body via dermal absorption, inhalation, or ingestion, causing multiple organ dysfunction, with severe neurological...